Momenta Pharmaceuticals (NASDAQ:MNTA) will be issuing its quarterly earnings data before the market opens on Monday, February 19th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $16.25 on Monday. Momenta Pharmaceuticals has a 1 year low of $11.85 and a 1 year high of $19.55. The company has a market cap of $1,241.29, a P/E ratio of -20.31 and a beta of 1.80.
MNTA has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. BidaskClub cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating and ten have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $15.30.
TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/momenta-pharmaceuticals-mnta-to-release-quarterly-earnings-on-monday.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.